ANTEOTECH LTD — Board/Management Information 2016

Nov 29, 2016

==> picture [315 x 91] intentionally omitted <==

Appointment of New Chairman

30 November 2016

Anteo Diagnostics Limited (ASX: ADO) announces the appointment of Dr John Hurrell as NonExecutive Chairman of the Anteo Group. Dr Hurrell has more than 30 years’ experience in the global biotechnology and life science industries. Dr Hurrell has served on the Anteo Board for over 3 years and is very familiar with the company and its technologies. He has a strong track record of success in starting, building, growing and improving the profitability, performance and value of life science and healthcare companies. Currently Dr Hurrell is a Consultant to PTS Diagnostics Inc. and serves as both President, Asia Pacific Region and Chairman, PTS Diagnostics India Pvt. Ltd.

Given Dr Hurrell’s appointment as Chairman, he will resign as a member of the Audit & Risk Committee and will be replaced on this committee by Mr Rolf Sickman.

“The Anteo Group is an exciting business with significant opportunity for growth. The acquisition of DIAsource at the start of the year was a strategic move for the Group providing new technology, infrastructure and geographic resources to Anteo. We still have some significant funding obligations related to this acquisition and the Board is currently addressing these. Given the changes at Board level and the recent appointments to the executive team, I have asked Dr Jef Vangenechten, Group CEO, and Mr Peter Harding-Smith, Group CFO, to work with the executive staff to undertake a thorough strategic review of the current and near term challenges and opportunities along with available options” said Dr Hurrell.

About Anteo Group – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology company which, through its diagnostics group, is developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets. In addition the Group is expanding the application of its technology into the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns patented nanochemistry surface engineering technology which combines the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents, binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

DIAsource ImmunoAssays SA, the wholly owned subsidiary of the Anteo Group, manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 counties around the world. DIAsource products include antibodies, assay kits and laboratory automation instrumentation.

For more information, please visit www.anteodx.com

==> picture [595 x 139] intentionally omitted <==